PDCD1 and non-small cell lung carcinoma: For example, regarding triple‐negative breast cancer and NSCLC, the PD‐L1 inhibitor atezolizumab and the PD‐1 inhibitor pembrolizumab are only indicated for patients whose tumors express PD‐L1.28, 29